259 Shares in Medpace Holdings, Inc. (NASDAQ:MEDP) Acquired by Nemes Rush Group LLC

Nemes Rush Group LLC bought a new position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) during the fourth quarter, Holdings Channel reports. The fund bought 259 shares of the company’s stock, valued at approximately $86,000.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its stake in shares of Medpace by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 2,570,770 shares of the company’s stock worth $854,087,000 after purchasing an additional 25,704 shares during the last quarter. State Street Corp grew its position in shares of Medpace by 7.2% in the 3rd quarter. State Street Corp now owns 752,957 shares of the company’s stock valued at $251,337,000 after buying an additional 50,312 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Medpace by 7.6% in the third quarter. Geode Capital Management LLC now owns 628,054 shares of the company’s stock valued at $209,885,000 after buying an additional 44,371 shares during the period. Wellington Management Group LLP increased its stake in shares of Medpace by 36.0% in the third quarter. Wellington Management Group LLP now owns 415,255 shares of the company’s stock valued at $138,612,000 after buying an additional 109,886 shares during the period. Finally, GW&K Investment Management LLC raised its position in shares of Medpace by 93.9% during the fourth quarter. GW&K Investment Management LLC now owns 275,460 shares of the company’s stock worth $91,516,000 after acquiring an additional 133,379 shares during the last quarter. 77.98% of the stock is currently owned by institutional investors and hedge funds.

Medpace Trading Up 4.5 %

MEDP opened at $311.23 on Thursday. The company has a fifty day moving average price of $333.58 and a two-hundred day moving average price of $338.33. Medpace Holdings, Inc. has a 1-year low of $289.01 and a 1-year high of $459.77. The company has a market cap of $9.48 billion, a P/E ratio of 24.64, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP) last issued its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research firms have weighed in on MEDP. Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Leerink Partners initiated coverage on shares of Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of Medpace to a “hold” rating in a report on Monday, March 24th. Nine analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $376.30.

Medpace Company Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.